Shots:
- The CHMP has recommended Opdivo + Pt-based CT as neoadj. followed by Opdivo alone as adj. treatment of adults with resectable NSCLC at high risk of recurrence & PD-L1 expression ≥1%. If approved, EC’s decision would be valid in all 30 EEA states
- The P-III (CheckMate-77T) study assessed neoadj. Opdivo + CT, followed by surgery & adj. Opdivo alone vs CT & PBO in 461 pts with resectable stage IIA to IIIB NSCLC
- Trial showed improved EFS (1EP), along with improvements in 2EPs of pCR & major pathologic response (MPR), while OS remains under assessment; data was presented at ESMO congress 2023 & published in The NEJM
Ref: BMS | Image: BMS
Related News:- BMS Reports the EC’s Approval of Breyanzi to Treat R/R Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
